Glycine transporter 1 is a target for the treatment of epilepsy
Shen HY, van Vliet EA, Bright KA, Hanthorn M, Lytle NK, Gorter J, Aronica E, Boison D
Contributed by Sloka Iyengar
Neuropharmacology Volume 99, Pages 554-565 December 2015 Available online August 2015
Glycine is an important modulator of synaptic plasticity in the hippocampus, but its role in epilepsy is not very well understood. In a recent study, the authors used two models of TLE – the intrahippocampal kainic acid model in mice and tetanic stimulation in rats, and observed effects on the glycine transporter 1 (GlyT1). In both rats and mice, the authors found an increase in protein levels of GlyT1. An increase in mRNA for GlyT1 was found in tissue resected from subjects with TLE. In a third experiment, mice with genetic deletion of GlyT1 in hippocampus and those administered the GlyT1 inhibitor LY showed an increased seizure threshold suggestive of a protective effect of decreasing glycine activity. Hence, the GlyT1 could be a potential novel target for development of new AEDs.
Subscribe to the ILAE Newsletter
To subscribe, please click on the button below.
Please send me information about ILAE activities and other
information of interest to the epilepsy community